Compugen post Q1 loss along with updates on clinical progress
Compugen (NASDAQ:CGEN) reported a net loss for the first quarter of 2026, alongside a stable cash position expected to sustain its clinical-stage pipeline into 2029.
The Holon, Israel-based biotechnology firm posted first-quarter revenue of $2.2 million, primarily driven by partner-related licensing streams.
Total research and development expenses reached $6.9 million, while general and administrative costs stood at $2.3 million, culminating in a quarterly net loss of $7.7 million, or $0.08 per share.
The company concluded the quarter with cash, cash equivalents, short-term bank deposits, and marketable securities totaling $134.9 million.
Operating with no corporate debt, Compugen expects its current capitalization to fund all ongoing operational requirements through key clinical readouts.
Operationally, the firm is advancing several high-priority oncology programs.
Its wholly owned COM701 MAIA-ovarian platform trial is actively enrolling patients across clinical sites in the U.S., Israel, and France, with a preliminary interim analysis on track for completion by the first quarter of 2027.
Concurrently, the company's major pharmaceutical collaborations are moving forward.
AstraZeneca is currently evaluating the licensed bispecific antibody rilvegostomig across 11 distinct Phase 3 clinical trials, while a Phase 1 study for the Gilead-partnered antibody therapy GS-0321 remains underway.
Together, the AstraZeneca and Gilead alliances represent approximately $1 billion in potential near- and long-term milestone payments for Compugen, in addition to tiered commercial royalties.
